Cdkn2A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CDKN2A encodes p16, a tumor suppressor that inhibits CDK4 and CDK6. It controls G1 cell cycle progression. p16 is involved in cellular senescence and aging. Studies suggest CDKN2A variants may influence Parkinson disease risk.
CDKN2A is involved in various cellular processes relevant to neurodegenerative disease research.
CDKN2A encodes p16, a tumor suppressor that inhibits CDK4 and CDK6. It controls G1 cell cycle progression. p16 is involved in cellular senescence and aging. Studies suggest CDKN2A variants may influence Parkinson disease risk.
Ubiquitously expressed, increases with age.
The study of Cdkn2A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.